MONMOUTH JUNCTION, N.J.,
Nov. 21, 2014 /PRNewswire/
-- CytoSorbents Corporation (OTCQB: CTSO), a critical care
immunotherapy company commercializing its European Union approved
CytoSorb® cytokine adsorber to treat critically-ill patients in
multiple countries worldwide, was awarded the Beacon of Light Award
at last night's New Jersey Tech Council Annual Awards
Celebration.
Dr. Phillip Chan, Chief Executive
Officer of CytoSorbents stated, "It is an honor to be recognized by
the New Jersey Tech Council and the judging committee as the winner
of the Beacon of Light award. At the company, we are all driven by
the desire to help give critically-ill patients a fighting chance
to survive life-threatening illnesses such as sepsis, trauma, lung
injury, burn injury, and pancreatitis. To shine a guiding
light and offer hope to physicians, patients and their families,
where today there is still so much darkness."
Dr. Chan continued, "We are grateful that CytoSorb® is being
used by a growing number of physicians in many hospitals around the
world to help stabilize patients in the intensive care unit and
during high risk cardiac surgery. The goal is to prevent
or treat multiple-organ failure, the leading cause of death in the
ICU for which there is little to no effective treatment. This
award is dedicated to the tireless efforts of the CytoSorbents team
- from its internal leadership to its manufacturing, research
and development, quality control, and sales and marketing
departments - as well as to the Company's shareholders,
distributors, and strategic partners whose support we truly
appreciate."
About the New Jersey Tech Council
The New Jersey Tech Council is a not-for-profit, trade
association focused on connecting decision-makers and
thought-leaders from life sciences, technology, and technology
support companies through access to financing opportunities,
networking, and business support. With an active calendar of
events and programs – more than 100 opportunities to connect with
peers, potential clients, strategic partners, vendors and
employment prospects – the New Jersey Tech Council provides vital
business information to help its members grow and flourish.
With more than 900 member businesses, ranging from small to
large well-known corporations such as Verizon, Comcast, Qualcomm,
and PSE&G, the New Jersey Tech Council supports a vibrant
business community in New
Jersey.
About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused
immunotherapy company using blood purification to control severe
inflammation -- with the goal of preventing or treating multiple
organ failure in life-threatening illnesses. Organ failure is the
cause of nearly half of all deaths in the intensive care unit, with
little to improve clinical outcome. CytoSorb®, the Company's
flagship product, is approved in the European Union as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation,
organ failure and death in common critical illnesses such as
sepsis, burn injury, trauma, lung injury, and pancreatitis. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb® is also being used
during and after cardiac surgery to remove inflammatory mediators,
such as cytokines and free hemoglobin, which can lead to
post-operative complications, including multiple organ
failure.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. CytoSorbents has numerous products
under development based upon this unique blood purification
technology, protected by 32 issued US patents and multiple
applications pending, including HemoDefend™, ContrastSorb,
DrugSorb, and others. Additional information is available for
download on the Company's website:
http://www.cytosorbents.com/.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 31, 2014, as updated
by the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We caution
you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required
under the Federal securities laws.
Please Click to Follow us on Facebook and
Twitter
Logo -
http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
SOURCE CytoSorbents Corporation